Foundry Healthcare OCFP Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1PFE | PFIZER INC | Healthcare | $142.77B | 9.26% |
2CVS | CVS HEALTH CORP | Healthcare | $137.12B | 8.89% |
3BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 8.04% |
4MDT | MEDTRONIC PLC | Healthcare | $106.50B | 6.91% |
5HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 5.34% |
6ELV | ELEVANCE HEALTH INC | Healthcare | $80.92B | 5.25% |
7CI | CIGNA GROUP | Healthcare | $74.45B | 4.83% |
8REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 4.60% |
9BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 4.24% |
10CAH | CARDINAL HEALTH INC | Healthcare | $53.52B | 3.47% |
11BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 2.83% |
12IQV | IQVIA HOLDINGS INC | Healthcare | $34.42B | 2.23% |
13RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 2.17% |
14CNC | CENTENE CORP | Healthcare | $32.81B | 2.13% |
15ZTS | ZOETIS INC | Healthcare | $32.10B | 2.08% |
16BIIB | BIOGEN INC | Healthcare | $30.41B | 1.97% |
17GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 1.86% |
18DGX | QUEST DIAGNOSTICS INC | Healthcare | $23.32B | 1.51% |
19LH | LABCORP HOLDINGS INC | Healthcare | $23.24B | 1.51% |
20UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 1.47% |
21VTRS | VIATRIS INC | Healthcare | $20.14B | 1.31% |
22ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $17.63B | 1.14% |
23THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 1.09% |
24JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 1.01% |
25DVA | DAVITA INC | Healthcare | $15.21B | 0.99% |
26EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.91% |
27COO | COOPER COMPANIES INC | Healthcare | $13.99B | 0.91% |
28BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.76% |
29BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.75% |
30EHC | ENCOMPASS HEALTH CORP | Healthcare | $11.13B | 0.72% |
31GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.68% |
32HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.60% |
33UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.59% |
34OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 0.57% |
35ATR | APTARGROUP INC | Healthcare | $8.46B | 0.55% |
36PACS | PACS GROUP INC | Healthcare | $7.30B | 0.47% |
37RDNT | RADNET INC | Healthcare | $4.89B | 0.32% |
38MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $4.41B | 0.29% |
39WAY | WAYSTAR HOLDING CORP | Healthcare | $4.27B | 0.28% |
40CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.26% |
41DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.26% |
42OGN | ORGANON & CO | Healthcare | $3.55B | 0.23% |
43HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.23% |
44OPCH | OPTION CARE HEALTH INC | Healthcare | $3.41B | 0.22% |
45XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.18% |
46TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.17% |
47ASTH | ASTRANA HEALTH INC | Healthcare | $2.50B | 0.16% |
48PGNY | PROGYNY INC | Healthcare | $2.50B | 0.16% |
49PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.15% |
50BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.15% |
51MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.14% |
52ADUS | ADDUS HOMECARE CORP | Healthcare | $2.14B | 0.14% |
53AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.14% |
54SGRY | SURGERY PARTNERS INC | Healthcare | $2.09B | 0.14% |
55OMCL | OMNICELL INC | Healthcare | $2.09B | 0.14% |
56AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.13% |
57HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.13% |
58SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.12% |
59ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.12% |
60HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.11% |
61TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.11% |
62FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.11% |
63INVA | INNOVIVA INC | Healthcare | $1.60B | 0.10% |
64SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.10% |
65AHCO | ADAPTHEALTH CORP | Healthcare | $1.49B | 0.10% |
66PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.10% |
67INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.09% |
68ARDT | ARDENT HEALTH INC | Healthcare | $1.46B | 0.09% |
69AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.09% |
70CNMD | CONMED CORP | Healthcare | $1.30B | 0.08% |
71COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.08% |
72NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.07% |
73USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.12B | 0.07% |
74CERT | CERTARA INC | Healthcare | $1.08B | 0.07% |
75PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.07% |
76BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.07% |
77TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.06% |
78AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.06% |
79HSTM | HEALTHSTREAM INC | Healthcare | $832M | 0.05% |
80RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.05% |
81CSTL | CASTLE BIOSCIENCES INC | Healthcare | $733M | 0.05% |
82PHR | PHREESIA INC | Healthcare | $662M | 0.04% |
83CRMD | CORMEDIX INC | Healthcare | $661M | 0.04% |
84CTEV | CLARITEV CORP | Healthcare | $518M | 0.03% |
85OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.03% |
86VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.03% |
87PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.03% |
88CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.03% |
89EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.03% |
90TBRG | TRUBRIDGE INC | Healthcare | $394M | 0.03% |
91SLP | SIMULATIONS PLUS INC | Healthcare | $369M | 0.02% |
92SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.01% |
93INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
94OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.01% |
95SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.54T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 37% toward Growth. +3% unclassified (13 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 24%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 49.8% | -47.6% |
| 3 yearsp.a. | 15.8% | -18.8% |
| 5 yearsp.a. | 10.6% | -11.4% |
| 10 yearsp.a. | 11.3% | -8.9% |
| Since inceptionp.a. | 15.5% | -3.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 15.0% | -29.8% |
| 2025 | 24.7% | -16.0% |
| 2024 | 4.1% | 0.1% |
| 2023 | -2.3% | -30.4% |
| 2022 | 6.5% | 14.5% |
| 2021 | 24.7% | 42.3% |
| 2020 | 10.6% | -12.7% |
| 2019 | 18.1% | -21.3% |
| 2018 | 6.0% | 20.3% |
| 2017 | 16.5% | -15.3% |
| 2016 | -2.9% | 3.1% |
| 2015 | 7.7% | -7.2% |
| 2014 | 25.0% | -24.4% |
| 2013 | 50.9% | -2.7% |
| 2012 | 19.8% | -12.5% |
| 2011 | 24.3% | 41.3% |
| 2010 | 19.1% | 2.7% |
| 2009 | 36.7% | 12.2% |
| 2008 | -16.6% | 35.8% |
| 2007 | 2.4% | 17.1% |
| 2006 | 20.8% | 14.4% |
| 2005 | 10.5% | 18.8% |
| 2004 | 8.2% | -1.9% |
| 2003 | 39.0% | -15.9% |
| 2002 | 2.3% | 39.7% |
| 2001 | 18.0% | 12.6% |
| 2000 | 77.5% | -60.5% |
| 1999 | -2.0% | -32.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare OCFP Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a OCFP signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.